Feasibility Study of Collecting Multicenter Chronic GVHD Data

Status Completed

Clinical Trial Summary

Primary Objective:

1. To determine the feasibility of conducting a multi-site longitudinal observational study of patients with chronic graft-versus-host disease (GVHD).

Clinical Trial Description

If you agree to take part in this study, you will be asked to fill-out some questionnaires, and your medical records will be reviewed. Your doctor or healthcare provider will also be asked to complete a questionnaire.

You will be asked to fill-out questionnaires at 3 different times (when you join this study, 3 months later, and 6 months later). The questionnaires will include questions about how your chronic GvHD impacts your body, your day-to-day activities, your emotions and perceptions, and your social and sexual life. Each questionnaire has 195 questions. Each should take about 20-30 minutes to complete, but you will also be asked how long it takes you to complete each questionnaire. For most participants, these visits will be part of your routine schedule for follow-up for the disease.

You have several options for where you may choose to complete the questionnaires. They may be completed when you visit the doctor for your appointments, at home (you will have to mail them back in self-addressed stamped envelopes that will be provided to you), or over the internet. If you are interested in the internet option, please ask study staff for more details. If at any time, your healthcare provider does not think it would be in your best interest to receive a survey at one of your scheduled time points, you will not be given a survey at that time, and you will be taken off this study.

Your healthcare provider will be asked to fill-out a questionnaire that asks about what was found on your physical exam and routine laboratory tests, what medications you are taking, and how severe your chronic GvHD is at that clinic visit.

Your medical records will be reviewed for about 1 year after your enrollment in this study to collect information about your stem cell transplant procedure, your medications, your medical condition, and the results of tests and procedures. The reviewing of your medical records does not require your active participation.

You will be on this study until you have completed the 6-month questionnaire.

This is an investigational study. There is no cost involved for participation in this study. Up to 40 participants will take part in this multicenter study. Up to 15 will be enrolled M. D. Anderson. ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00506233
Study type	Observational
Source	M.D. Anderson Cancer Center
Contact
Status	Completed
Phase	N/A
Start date	August 2006

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT01428973` - Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens	Phase 2
Not yet recruiting	`NCT00749164` - Allogeneic Mesenchymal Stem Cell for Graft-Versus-Host Disease Treatment	Phase 1/Phase 2
Completed	`NCT00993343` - Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation	Phase 3
Completed	`NCT00360685` - Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX	N/A
Active, not recruiting	`NCT04503616` - Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention	Phase 1/Phase 2
Terminated	`NCT02080195` - Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)	Phase 1/Phase 2
Completed	`NCT02193880` - Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT)	N/A
Completed	`NCT02942173` - CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT	Phase 2/Phase 3
Completed	`NCT02145403` - Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies	Phase 1/Phase 2
Recruiting	`NCT01941394` - Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation	Phase 2
Completed	`NCT00141713` - The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease	Phase 2
Recruiting	`NCT01991301` - Carfilzomib for the Prevention of Graft Versus Host Disease	Phase 1
Completed	`NCT00408928` - Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease	Phase 2
Completed	`NCT01633229` - Bone Marrow Stromal Cell Infusions for Stem Cell Transplant Complications	Phase 1
Completed	`NCT05856058` - To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability	Phase 1
Completed	`NCT02342613` - Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation	Phase 1
Recruiting	`NCT06423131` - Prospective Clinical Trial for Children With TCRαβ Depleted vs Traditional Haplo Identicle HSCT	N/A
Completed	`NCT02144025` - Prevention of Ocular Graft-Versus-Host Disease With Topical Cyclosporine in Recipients of Allogeneic HSCT	Phase 2
Completed	`NCT01369914` - The Natural History of Graft-Versus-Host Disease in the Eyes
Completed	`NCT00806728` - Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease	Phase 1